Department of Biology, Faculty of Arts and Science, Aydin Adnan Menderes University, Aydin, Türkiye.
Department of Parasitology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Türkiye.
Sci Rep. 2022 Jun 24;12(1):10779. doi: 10.1038/s41598-022-13722-z.
Natural products have been proven to be important starting points for the development of new drugs. Bacteria in the genera Photorhabdus and Xenorhabdus produce antimicrobial compounds as secondary metabolites to compete with other organisms. Our study is the first comprehensive study screening the anti-protozoal activity of supernatants containing secondary metabolites produced by 5 Photorhabdus and 22 Xenorhabdus species against human parasitic protozoa, Acanthamoeba castellanii, Entamoeba histolytica, Trichomonas vaginalis, Leishmania tropica and Trypanosoma cruzi, and the identification of novel bioactive antiprotozoal compounds using the easyPACId approach (easy Promoter Activated Compound Identification) method. Though not in all species, both bacterial genera produce antiprotozoal compounds effective on human pathogenic protozoa. The promoter exchange mutants revealed that antiprotozoal bioactive compounds produced by Xenorhabdus bacteria were fabclavines, xenocoumacins, xenorhabdins and PAX peptides. Among the bacteria assessed, only P. namnaoensis appears to have acquired amoebicidal property which is effective on E. histolytica trophozoites. These discovered antiprotozoal compounds might serve as starting points for the development of alternative and novel pharmaceutical agents against human parasitic protozoa in the future.
天然产物已被证明是开发新药的重要起点。光单胞菌属和异单胞菌属中的细菌会产生抗菌化合物作为次级代谢产物,以与其他生物竞争。我们的研究首次全面筛选了 5 种光单胞菌属和 22 种异单胞菌属产生的次级代谢产物上清液对人体寄生虫原生动物、耐格里阿米巴、溶组织内阿米巴、阴道毛滴虫、热带利什曼原虫和克氏锥虫的抗原生动物活性,并使用 easyPACId 方法(易启动子激活化合物鉴定)方法鉴定新型生物活性抗原生动物化合物。虽然不是所有物种都产生对人体致病原生动物有效的抗原生动物化合物,但这两个细菌属都产生了抗原生动物的化合物。启动子交换突变体表明,异单胞菌属细菌产生的抗原生动物生物活性化合物为 Fabclavines、Xenocoumacins、Xenorhabdins 和 PAX 肽。在所评估的细菌中,只有 P. namnaoensis 似乎获得了杀阿米巴特性,对溶组织内阿米巴滋养体有效。这些发现的抗原生动物化合物可能成为未来针对人体寄生虫原生动物开发替代和新型药物制剂的起点。